Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1. Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies.

Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies. Background: Parity is widely recognized as protective for breast cancer, but breast cancer risk may be increased shortly after childbirth. Whether this risk varies with breastfeeding, family history of breast cancer, or specific tumor subtype has rarely been evaluated. Objective: To characterize breast cancer risk in relation to recent childbirth. Design: Pooled analysis of individual-level data from 15 (...) prospective cohort studies. Setting: The international Premenopausal Breast Cancer Collaborative Group. Participants: Women younger than 55 years. Measurements: During 9.6 million person-years of follow-up, 18 826 incident cases of breast cancer were diagnosed. Hazard ratios (HRs) and 95% CIs for breast cancer were calculated using Cox proportional hazards regression. Results: Compared with nulliparous women, parous women had an HR for breast cancer that peaked about 5 years after birth (HR, 1.80 [95% CI

Annals of Internal Medicine2018

2. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. BACKGROUND: Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)-targeted therapy have a worse prognosis than those who have no residual cancer. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate of trastuzumab and the cytotoxic agent emtansine (DM1), a maytansine derivative and microtubule inhibitor, provides benefit (...) in patients with metastatic breast cancer that was previously treated with chemotherapy plus HER2-targeted therapy. METHODS: We conducted a phase 3, open-label trial involving patients with HER2-positive early breast cancer who were found to have residual invasive disease in the breast or axilla at surgery after receiving neoadjuvant therapy containing a taxane (with or without anthracycline) and trastuzumab. Patients were randomly assigned to receive adjuvant T-DM1 or trastuzumab for 14 cycles

NEJM2018

3. HER2 Testing in Breast Cancer - 2018 Focused Update

HER2 Testing in Breast Cancer - 2018 Focused Update HER2 Testing in Breast Cancer -… | College of American Pathologists Cap icon Group CAP_logo_rgb[1] User Toggle Navigation Menu Search Down Arrow Down Arrow Down Arrow Down Arrow Down Arrow Down Arrow Down Arrow HER2 Testing in Breast Cancer - 2018 Focused Update HER2 Testing in Breast Cancer - 2018 Focused Update To address new information made available since the 2013 “Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer (...) 2+ (equivocal) to the original FDA-approved criteria. Repeat HER2 testing on a surgical specimen if the initially tested core biopsy is negative is no longer stated as mandatory. A new HER2 test may (no longer should ) be ordered on the excision specimen on the basis of some criteria (such as tumor grade 3). A more rigorous interpretation criteria of the less common patterns that can be seen in about 5% of all cases when HER2 status in breast cancer is evaluated using a dual-probe ISH testing

College of American Pathologists2018

4. Risk factors for breast cancer: A review of the evidence 2018

Risk factors for breast cancer: A review of the evidence 2018 Risk factors for breast cancer: A review of the evidence 2018 Breast cancer risk factors: A review of the evidence i Risk factors for breast cancer: A review of the evidence was prepared and produced by: Cancer Australia Locked Bag 3 Strawberry Hills NSW 2012 Australia Tel: +61 2 9357 9400 Fax: +61 2 9357 9477 canceraustralia.gov.au © Cancer Australia 2018. ISBN Print: 978–1–74127–336–6 ISBN Online: 978–1–74127–337–3 Recommended (...) citation Cancer Australia, 2018. Risk factors for breast cancer: A review of the evidence, Cancer Australia, Surry Hills, NSW. Risk factors for breast cancer: A review of the evidence can be downloaded from the Cancer Australia website: canceraustralia.gov.au Copyright statements Internet sites This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within

Cancer Australia2018

5. Recommendations on screening for breast cancer in women 40-74 years of age who are not at increased risk

Recommendations on screening for breast cancer in women 40-74 years of age who are not at increased risk Recommendations on screening for breast cancer in women aged 40–74 years who are not at increased risk for breast cancer | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Guideline Recommendations on screening for breast cancer in women aged 40–74 years who are not at increased risk for breast cancer Scott Klarenbach , Nicki Sims-Jones , Gabriela Lewin (...) POINTS Low-certainty evidence indicates that screening for breast cancer with mammography results in a modest reduction in breast cancer mortality for women aged 40 to 74 years; the absolute benefit is lowest for women younger than 50 years. Screening may lead to overdiagnosis, resulting in unnecessary treatment of cancer that would not have caused harm in a woman’s lifetime and false-positive results that can lead to both physical and psychological consequences; overdiagnosis and false-positives

Canadian Task Force on Preventive Health Care2018

6. Breast Cancer Risk Factors At a Glance

Breast Cancer Risk Factors At a Glance Age 50 years old 30 years old Height 172 cm 162 cm ( average female height in Australia ) Reproductive factors Family history and genetic factors Lifestyle factors Personal factors VS. VS. 152 cm 162 cm ( average female height in Australia ) Mammographic breast density VS. Extremely dense breasts averagely dense breasts VS. Body mass index ( postmenopausal women ) VS. Adult weight gain ( postmenopausal women ) Weight gain (5kg) no weight gain VS. Weight (...) gain (10kg) Weight gain (20kg) Alcohol consumption 2 drinks per day no daily alcohol consumption VS. Physical activity Most active least active ( postmenopausal women ) VS. 4 drinks per day 6 drinks per day Breast Cancer Risk Factors At a Glance Decreased risk Increased risk 1 2 3 4 5 6 7 8 910 0.5 0.33 0.25 0.2 0.125 0.1 10 1.17 0.85 2.14 1.12 1.25 1.40 1.06 1.12 1.26 1.15 1.31 1.50 0.87 VS. VS. no weight gain VS. no weight gain VS. no daily alcohol consumption VS. no daily alcohol consumption VS

Cancer Australia2018

7. Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer

Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer 30311642 2018 10 12 1365-2168 105 12 2018 Nov The British journal of surgery Br J Surg Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer. 1541-1552 10.1002/bjs.10986 Neoadjuvant chemotherapy for breast cancer has the potential to achieve a pathological complete (...) response in up to 40 per cent of patients, converting disease that was initially node-positive to node-negative. This has raised the question of whether sentinel lymph node biopsy could be an alternative to axillary lymph node dissection in these patients. The aim was to undertake a systematic review and meta-analysis of the accuracy and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer. A literature search

EvidenceUpdates2018

8. Limited Evidence Suggests Periodontal Disease Is Associated with a Slightly Increased Risk of Breast Cancer

Limited Evidence Suggests Periodontal Disease Is Associated with a Slightly Increased Risk of Breast Cancer UTCAT3364, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Limited Evidence Suggests Periodontal Disease Is Associated with a Slightly Increased Risk of Breast Cancer Clinical Question In female patients with periodontal disease, is there an increased risk for breast cancer when compared to women without (...) periodontal disease? Clinical Bottom Line Patients with periodontitis have a slightly increased risk of breast cancer according to limited evidence from one meta-analysis and a prospective cohort study. History of smoking may play a role in this relationship and more evidence is required before specific recommendations can be made to patients with periodontitis. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1

UTHSCSA Dental School CAT Library2018

9. Pertuzumab (Perjeta) - treatment of adult patients with HER2 positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence

Pertuzumab (Perjeta) - treatment of adult patients with HER2 positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence 1 Published 10 December 2018 1 SMC2119 pertuzumab 420mg concentrate for solution for infusion (Perjeta®) Roche Products Limited Resubmission 9 November 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use (...) in NHSScotland. The advice is summarised as follows: ADVICE: following a second resubmission assessed under the orphan medicine process pertuzumab (Perjeta ® ) is accepted for use within NHSScotland. Indication under review: for use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. In a phase II study conducted in women with locally advanced, inflammatory

Scottish Medicines Consortium2018

10. Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis

Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis 30312200 2018 10 12 1528-1140 2018 Oct 11 Annals of surgery Ann. Surg. Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis. 10.1097/SLA.0000000000003075 The aim of this study was to perform (...) a systematic review and meta-analysis to assess the accuracy of different surgical axillary staging procedures compared with ALND. Optimal axillary staging after neoadjuvant systemic therapy (NST) in node-positive breast cancer is an area of controversy. Several less invasive procedures, such as sentinel lymph node biopsy (SLNB), marking axillary lymph node with radioactive iodine seed (MARI), and targeted axillary dissection (a combination of SLNB and a MARI-like procedure), have been proposed to replace

EvidenceUpdates2018

11. Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis.

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis. BACKGROUND: Originator trastuzumab (Herceptin®; H) is an antibody-targeted therapy to treat patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC). We investigated the overall survival (OS) advantage conferred by the addition of H to chemotherapy for HER2+ EBC patients and how the OS advantage changed over time. METHODS: A systematic

Systematic Reviews2018

15. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial 30196031 2018 10 10 1474-5488 19 10 2018 Oct The Lancet. Oncology Lancet Oncol. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. 1385-1393 S1470-2045(18)30380-2 (...) 10.1016/S1470-2045(18)30380-2 We previously reported the 5-year results of the phase 3 IBCSG 23-01 trial comparing disease-free survival in patients with breast cancer with one or more micrometastatic (≤2 mm) sentinel nodes randomly assigned to either axillary dissection or no axillary dissection. The results showed no difference in disease-free survival between the groups and showed non-inferiority of no axillary dissection relative to axillary dissection. The current analysis presents the results

EvidenceUpdates2018

16. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Tr

First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Tr 30106636 2018 09 26 1527-7755 36 28 2018 Oct 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab (...) , in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. 2826-2835 10.1200/JCO.2017.76.7863 To assess pertuzumab plus trastuzumab and an aromatase inhibitor (AI) in patients with human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive metastatic/locally advanced breast cancer (MBC/LABC). The PERTAIN trial (NCT01491737) is an ongoing randomized, open

EvidenceUpdates2018

17. Implant Based Breast Reconstruction With Acellular Dermal Matrix: Safety Data From an Open-label, Multicenter, Randomized, Controlled Trial in the Setting of Breast Cancer Treatment

Implant Based Breast Reconstruction With Acellular Dermal Matrix: Safety Data From an Open-label, Multicenter, Randomized, Controlled Trial in the Setting of Breast Cancer Treatment 30308615 2018 10 19 1528-1140 2018 Oct 17 Annals of surgery Ann. Surg. Implant Based Breast Reconstruction With Acellular Dermal Matrix: Safety Data From an Open-label, Multicenter, Randomized, Controlled Trial in the Setting of Breast Cancer Treatment. 10.1097/SLA.0000000000003054 To evaluate clinical outcomes (...) of using acellular dermal matrix (ADM) with implant based breast reconstructions (IBBRs) in a randomized controlled trial. The use of ADMs in IBBRs is widespread, but link between ADM and complications remain a controversial topic. In view of reports concerning harm, we present 6-months safety data of ADM-assisted IBBR in the setting of breast cancer treatment. An open-label, randomized, controlled trial recruiting patients from 4 centers in Sweden and 1 in UK. Eligible were women with breast cancer

EvidenceUpdates2018

19. Delaying chemotherapy after breast cancer surgery may reduce survival chances

Delaying chemotherapy after breast cancer surgery may reduce survival chances Signal - Delaying chemotherapy after breast cancer surgery may reduce survival chances Dissemination Centre Discover Portal NIHR DC Discover Delaying chemotherapy after breast cancer surgery may reduce survival chances Published on 31 January 2017 Delaying chemotherapy after breast cancer surgery may slightly decrease a woman’s chances of survival. A review found about a 5% increase in the relative risk of death. Many (...) women are offered chemotherapy soon after breast cancer surgery, called adjuvant chemotherapy. Chemotherapy is usually started after the surgical wounds have healed but the effect of any delay to this was unclear. These researchers calculated the risk from outcomes for almost 30,000 women treated with adjuvant chemotherapy, from studies in Europe and North America. The absolute risk of death for any woman will depend on her individual cancer stage and characteristics. A four week delay could add

NIHR Dissemination Centre2018

20. Common osteoporosis drugs may prevent breast cancer spreading to bone

Common osteoporosis drugs may prevent breast cancer spreading to bone Signal - Common osteoporosis drugs may prevent breast cancer spreading to bone Dissemination Centre Discover Portal NIHR DC Discover Common osteoporosis drugs may prevent breast cancer spreading to bone Published on 13 March 2018 Drugs commonly prescribed to prevent bone thinning probably help prevent the spread of early breast cancer to the bones in a few women, when taken in addition to standard cancer therapies. However (...) , the overall benefits may be small, for example preventing spread to bone or death in about one extra woman in every 100 treated for about five years. This is a complex area because many of the treatments for breast cancer are known to worsen bone thinning, but there are other bone strengthening benefits to these drugs. This large review of 44 studies with more than 37,000 participants looked at women with either early breast cancer or advanced breast cancer with or without bone involvement. The reviewers

NIHR Dissemination Centre2018